Basevi V, Di Mario S, Morciano C, Nonino F, Magrini N Comment on: American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care 2011;34(Suppl. 1):S11-S61. Diabetes Care. 2011 May;34(5):e53; author reply e54. doi: 10.2337/dc11-0174. No abstract available. Erratum In: Diabetes Care. 2011 Aug;34(8):1887.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003 Apr 24;348(17):1625-38. doi: 10.1056/NEJMoa021423.
Dandona P, Chaudhuri A, Ghanim H, Mohanty P Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol. 2009 Feb 3;53(5 Suppl):S14-20. doi: 10.1016/j.jacc.2008.10.038.
Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care. 2003 May;26(5):1485-9. doi: 10.2337/diacare.26.5.1485.
Dinneen SF, Gerstein HC The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med. 1997 Jul 14;157(13):1413-8.
Dogne JM, Hanson J, Pratico D Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol Sci. 2005 Dec;26(12):639-44. doi: 10.1016/j.tips.2005.10.001. Epub 2005 Oct 21.
Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care. 2006 Jun;29(6):1214-9. doi: 10.2337/dc06-1910.
FLAT-SUGAR Trial Investigators Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. Diabetes Care. 2016 Jun;39(6):973
Hirsch IB, Brownlee M Beyond hemoglobin A1c--need for additional markers of risk for diabetic microvascular complications. JAMA. 2010 Jun 9;303(22):2291-2. doi: 10.1001/jama.2010.785. No abstract available.
Hirsch IB Blood glucose monitoring technology: translating data into practice. Endocr Pract. 2004 Jan-Feb;10(1):67-76. doi: 10.4158/EP.10.1.67.
Kadowaki T, Yamauchi T Adiponectin and adiponectin receptors. Endocr Rev. 2005 May;26(3):439-51. doi: 10.1210/er.2005-0005.
KDOQI KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007 Feb;49(2 Suppl 2):S12-154. doi: 10.1053/j.ajkd.2006.12.005. No abstract available.
Kovatchev BP, Clarke WL, Breton M, Brayman K, McCall A Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application. Diabetes Technol Ther. 2005 Dec;7(6):849-62. doi: 10.1089/dia.2005.7.849.
Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006 Apr 12;295(14):1681-7. doi: 10.1001/jama.295.14.1681.
Rodbard D New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther. 2009 Sep;11(9):551-65. doi: 10.1089/dia.2009.0015.
Rosenfeld SI, Packman CH, Leddy JP Inhibition of the lytic action of cell-bound terminal complement components by human high density lipoproteins and apoproteins. J Clin Invest. 1983 Apr;71(4):795-808. doi: 10.1172/jci110833.
Ruggenenti P, Remuzzi G Time to abandon microalbuminuria? Kidney Int. 2006 Oct;70(7):1214-22. doi: 10.1038/sj.ki.5001729. Epub 2006 Jul 26.
Shao B, Pennathur S, Pagani I, Oda MN, Witztum JL, Oram JF, Heinecke JW Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway. J Biol Chem. 2010 Jun 11;285(24):18473-84. doi: 10.1074/jbc.M110.118182. Epub 2010 Apr 8.
Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002 Apr;51(4):1157-65. doi: 10.2337/diabetes.51.4.1157.
Sun J, Xu Y, Deng H, Sun S, Dai Z, Sun Y Intermittent high glucose exacerbates the aberrant production of adiponectin and resistin through mitochondrial superoxide overproduction in adipocytes. J Mol Endocrinol. 2010 Mar;44(3):179-85. doi: 10.1677/JME-09-0088.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.